Effective management of peripheral vertigo due to benign paroxysmal positional vertigo with betahistine, in the real-world setting: an expert survey with ENT specialists in India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253150Keywords:
Betahistine, BPPV, Canalith repositioning maneuvers, Recurrence, Residual dizzinessAbstract
Background: Benign paroxysmal positional vertigo (BPPV) commonly causes peripheral vertigo and is treated with canalith repositioning maneuvers (CRM). Yet, a subset of patients continues to experience vertigo called residual dizziness after undergoing CRM. Objective was to understand the role of betahistine 48 mg per day in prevention of recurrent vertigo and prevention of residual dizziness in patients with BPPV based on expert perceptions.
Methods: Forty ear, nose and throat (ENT) specialists or otolaryngologists from diverse regions across India who were treating patients with peripheral vertigo were invited to participate in an online survey regarding their approach to treating peripheral vertigo in the real-world setting.
Results: 23 respondents (57%) reported that 10-25% of their patients had recurrence of vertigo. 24 respondents (60%) opined that both impaired vestibular compensation due to insufficient dose (less than 48 mg/day) and duration (less than 3 months) of betahistine and remnant otoliths cause recurrence of vertigo. 57% participants adopted this approach to prevent residual dizziness namely: 1) increase dose of betahistine to 48 mg/day and 2) increase the duration of use of betahistine to 3 months. 40% physicians opined that 75-90% reduction in vertigo episodes is seen with 48 mg per day of betahistine.
Conclusions: Betahistine is preferred to treat peripheral vertigo due to BPPV. Betahistine is prescribed in the dose of 48 mg per day for a duration of at least 3 months post repositioning manoeuvres effectively reduces vertigo, reduces recurrence and residual dizziness by facilitating vestibular compensation and improved vestibular blood supply.
Metrics
References
Wu P, Cao W, Hu Y, Li H. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning maneuvers in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial. BMJ Open. 2019;9(6):26711. DOI: https://doi.org/10.1136/bmjopen-2018-026711
Lindell E, Finizia C, Davidsson H, Kollen L, Kern S, Skoog I, et al. Prevalence of benign paroxysmal positional vertigo in a population-based setting among 75-year-olds. J Vestib Res. 2024;34(4):195-204. DOI: https://doi.org/10.3233/VES-240027
Ferreira AL, Windsor AM, Hwa TP, Wang SY, Field EW, Ruckenstein MJ, et al. Dizziness and imbalance across the lifespan: findings of a pediatric and adult vestibular clinic. Otolaryngol Head Neck Surg. 2025;172(1):254-61. DOI: https://doi.org/10.1002/ohn.962
Jeong SH, Kim JS, Kim HJ, Choi JY, Koo JW, Choi KD, et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: a randomized trial. Neurology. 2020;95:1117-25. DOI: https://doi.org/10.1212/WNL.0000000000010343
Froehling DA, Bowen JM, Mohr DN, Brey RH, Beatty CW, Wollan PC, et al. The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial. Mayo Clin Proceed. 2000;75(7):695-700. DOI: https://doi.org/10.1016/S0025-6196(11)64615-6
Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional vertigo (BPPV). CMAJ. 2003;169(7):681-93.
Helminski JO, Zee DS, Janssen I, Hain TC. Effectiveness of particle repositioning maneuvers in the treatment of benign paroxysmal positional vertigo: a systematic review. Phys Ther. 2010;90(5):663-78. DOI: https://doi.org/10.2522/ptj.20090071
Kerber KA, Burke JF, Skolarus LE, Meurer WJ, Callaghan BC, Brown DL, et al. Use of BPPV processes in emergency department dizziness presentations: a population-based study. Otolaryngol Head Neck Surg. 2013;148(3):425-30. DOI: https://doi.org/10.1177/0194599812471633
Tirelli G, Nicastro L, Gatto A, Tofanelli M. Repeated canalith repositioning maneuvers in BPPV: effects on recurrence and dizziness prevention. Am J Otolaryngol. 2017;38(1):38-43. DOI: https://doi.org/10.1016/j.amjoto.2016.09.009
Li JC. Mastoid oscillation: a critical factor for success in the canalith repositioning maneuvers. Otolaryngol Head Neck Surg. 1995;112(6):670-5. DOI: https://doi.org/10.1016/S0194-59989570174-5
Su P, Liu YC, Lin HC. Risk factors for the recurrence of post-semicircular canal benign paroxysmal positional vertigo after canalith repositioning. J Neurol. 2016;263(1):45-51. DOI: https://doi.org/10.1007/s00415-015-7931-0
Seok JI, Lee HM, Yoo JH, Lee DK. Residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. J Clin Neurol. 2008;4(3). DOI: https://doi.org/10.3988/jcn.2008.4.3.107
Martellucci S, Pagliuca G, de Vincentiis M, Greco A, De Virgilio A, Nobili Benedetti FM, et al. Features of residual dizziness after canalith repositioning procedures for benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2016;154(4):693-701. DOI: https://doi.org/10.1177/0194599815627624
Ismail NM, Kabil SE, Abdel-Hamid EF. Otolithic functions in patients with residual dizziness after successful repositioning maneuversfor unilateral posterior canal BPPV. J Int Med Res. 2024;52(5):3000605241249095. DOI: https://doi.org/10.1177/03000605241249095
Wu P, Yang J, Huang X, Ma Z, Zhang T, Li H. Predictors of residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a multi-center prospective cohort study. J Vestib Res. 2021;31(2):119-29. DOI: https://doi.org/10.3233/VES-201535
Raheja G. Peripheral vertigo and appropriate use of Betahistine to improve outcomes. Int J Res Med Sci. 2024;12(10):4006-10. DOI: https://doi.org/10.18203/2320-6012.ijrms20242978
Pollard H, Schwartz JC. Histamine neuronal pathways and their functions. Trends Neurosci. 1987;10(2):86-9. DOI: https://doi.org/10.1016/0166-2236(87)90031-2
Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res. 2013;23:139-51. DOI: https://doi.org/10.3233/VES-130496
Claes J. A review of medical treatment for Ménière’s disease. Acta Oto-Laryngol. 2000;120(544):34-9. DOI: https://doi.org/10.1080/000164800750044461
Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston LJ, Cass S, et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2008;139:47-81. DOI: https://doi.org/10.1016/j.otohns.2008.08.022
Califano L, Salafia F, Mazzone S, Melillo MG, Califano M. Anterior canal BPPV and apogeotropic posterior canal BPPV: two rare forms of vertical canalolithiasis. Acta Otorhinolaryngol Ital. 2014;34:189-97.
von Brevern M, Seelig T, Radtke A, Tiel-Wilck K, Neuhauser H, Lempert T. Short-term efficacy of Epley’s manoeuvre: a double-blind randomised trial. J Neurol Neurosurg Psychiatr. 2006;77:980-2. DOI: https://doi.org/10.1136/jnnp.2005.085894
Gordon CR, Gadoth N. Repeated vs single physical maneuver in benign paroxysmal positional vertigo. Acta Neurol Scand. 2004;110:166-9. DOI: https://doi.org/10.1111/j.1600-0404.2004.00296.x
Ke Y, Ma X, Jing Y, Diao T, Yu L. Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis. Eur Arch Otorrinolaringol. 2022;279:3237-56. DOI: https://doi.org/10.1007/s00405-022-07288-9
Özgirgin ON, Kingma H, Manzari L, Lacour M. Residual dizziness after BPPV management: exploring pathophysiology and treatment beyond canalith repositioning maneuvers. Front Neurol. 2024;15:1382196. Erratum in: Front Neurol. 2024;15:1461600. DOI: https://doi.org/10.3389/fneur.2024.1382196
Strupp M, Churchill GC, Naumann I, Mansmann U, Al Tawil A, Golentsova A, et al. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST). Front Neurol. 2023;14:1271640. DOI: https://doi.org/10.3389/fneur.2023.1271640
Zamergrad MV, Kunelskaya NL, Guseva AL, Amelin AV, Lilenko SV, Samartcev IN, et al. Betahistine in vestibular disorders: current concepts and perspectives. Vestn Otorinolaringol. 2021;86(2):73-81. DOI: https://doi.org/10.17116/otorino20218602173
Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, Cardenas Nuñez JL, Rodríguez Montoya V, Deschamps JJ, et al. Use of betahistine in the treatment of peripheral vertigo. Acta Oto-laryngologica. 2015;135(12):1205-11. DOI: https://doi.org/10.3109/00016489.2015.1072873
Benny R. Expert opinions regarding neuro-microcirculatory, vestibular and labyrinthine dynamics in benign paroxysmal positional vertigo. Int J Res Med Sci. 2022;10:796-800. DOI: https://doi.org/10.18203/2320-6012.ijrms20220541
Lacour M, Helmchen C, Vidal PP. Vestibular compensation: the neuro-otologist’s best friend. J Neurol. 2016;263:54-64. DOI: https://doi.org/10.1007/s00415-015-7903-4
Jalali MM, Gerami H, Saberi A, Razaghi S. The impact of betahistine versus dimenhydrinate in the resolution of residual dizziness in patients with benign paroxysmal positional vertigo: a randomized clinical trial. Ann Oto Rhino Laryngol. 2020;129(5):434-40. DOI: https://doi.org/10.1177/0003489419892285
Downloads
Published
How to Cite
Issue
Section
